| 7.7 0.14 (1.85%) | 06-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 12.47 | 1-year : | 15.04 |
| Resists | First : | 10.68 | Second : | 12.88 |
| Pivot price | 8.43  |
|||
| Supports | First : | 7.11 | Second : | 5.92 |
| MAs | MA(5) : | 7.64 |
MA(20) : | 9.15 |
| MA(100) : | 9.11 |
MA(250) : | 9.96 |
|
| MACD | MACD : | -0.8 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 8.4 |
D(3) : | 9.2 |
| RSI | RSI(14): 39.3 |
|||
| 52-week | High : | 20.55 | Low : | 6.71 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CRBP ] has closed above bottom band by 36.1%. Bollinger Bands are 116.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 17 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 7.95 - 7.98 | 7.98 - 8.01 |
| Low: | 7.37 - 7.41 | 7.41 - 7.44 |
| Close: | 7.64 - 7.7 | 7.7 - 7.75 |
Corbus Pharmaceuticals Holdings, Inc. operates as a biopharmaceutical firm, concentrating on creating immune modulators designed to combat immuno-oncology and various fibrotic conditions. Its pipeline includes lenabasum, an orally administered small molecule. This compound selectively activates cannabinoid receptor type 2 (CB2) and is currently undergoing Phase II clinical trials for the treatment of systemic lupus erythematosus. The company is also advancing CRB-601, an anti-integrin monoclonal antibody (mAb) engineered to inhibit the activation of transforming growth factor ß (TGFß), which it is developing for both cancer and fibrotic indications. Another key asset is CRB-602, an anti-avß6/avß8 mAb designed to block TGFß activation, specifically for addressing fibrotic diseases. Beyond these, Corbus is pursuing a cannabinoid receptor type 1 inverse agonist program. This broad-spectrum initiative targets several conditions, including metabolic disorders such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; various fibrotic diseases, like lung, cardiac, renal, and liver fibrosis; and other ailments, including ascites, cognitive impairments, Prader-Willi syndrome, and smoking cessation. In terms of collaborations, Corbus has a licensing agreement with Jenrin Discovery, LLC. This partnership grants them rights to develop and commercialize products, encompassing Jenrin's extensive library of approximately 600 compounds, alongside numerous issued and pending patent applications. Established in 2009, the company's headquarters are located in Norwood, Massachusetts.
Mon, 08 Jun 2026
Insider Spends US$101k Buying More Shares In Corbus Pharmaceuticals Holdings - simplywall.st
Fri, 05 Jun 2026
Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch
Thu, 04 Jun 2026
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Wed, 03 Jun 2026
Corbus (CRBP) Chief Business Officer buys 13,500 shares in open market - Stock Titan
Wed, 03 Jun 2026
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Fri, 29 May 2026
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Stock Price Today & Analysis - Gotrade
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 19 (M) |
| Shares Float | 13 (M) |
| Held by Insiders | 1 (%) |
| Held by Institutions | 72 (%) |
| Shares Short | 1,200 (K) |
| Shares Short P.Month | 1,340 (K) |
| EPS | -5.74 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.11 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -39.5 % |
| Return on Equity (ttm) | -66.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -3.79 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.84 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -1.35 |
| PEG Ratio | 0 |
| Price to Book value | 1.08 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|